{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:09Z","timestamp":1761870549632,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.clml.2012.11.004","type":"journal-article","created":{"date-parts":[[2012,12,29]],"date-time":"2012-12-29T02:18:00Z","timestamp":1356747480000},"page":"139-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clofarabine Does Not Negatively Impact the Outcomes of Patients With Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation"],"prefix":"10.1016","volume":"13","author":[{"given":"Michael S.","family":"Mathisen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2012.11.004_bib1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia","volume":"331","author":"Mayer","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.11.004_bib2","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","article-title":"Cytarabine dose for acute myeloid leukemia","volume":"364","author":"L\u00f6wenberg","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.11.004_bib3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.11.004_bib4","doi-asserted-by":"crossref","first-page":"280","DOI":"10.6004\/jnccn.2011.0027","article-title":"Acute myeloid leukemia","volume":"9","author":"O'Donnell","year":"2011","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.clml.2012.11.004_bib5","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.11.004_bib6","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"L\u00f6wenberg","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.11.004_bib7","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/cncr.21005","article-title":"The role of clofarabine in hematologic and solid malignancies\u2014development of a next-generation nucleoside analog","volume":"103","author":"Faderl","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2012.11.004_bib8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00280-004-0906-y","article-title":"Biochemical modulation of cytarabine triphosphate by clofarabine","volume":"55","author":"Cooper","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"year":"2010","series-title":"Clolar (clofarabine) package insert","key":"10.1016\/j.clml.2012.11.004_bib9"},{"key":"10.1016\/j.clml.2012.11.004_bib10","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1182\/blood-2011-08-374710","article-title":"Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"118","author":"Hijiya","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.11.004_bib11","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.clml.2012.11.004_bib12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2012.11.004_bib13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.1840040121","article-title":"Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors","volume":"4","author":"McDonald","year":"1984","journal-title":"Hepatology"},{"key":"10.1016\/j.clml.2012.11.004_bib14","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","article-title":"Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation","volume":"102","author":"Wadleigh","year":"2003","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012002479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012002479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:24:20Z","timestamp":1761870260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265012002479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S2152265012002479"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2012.11.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clofarabine Does Not Negatively Impact the Outcomes of Patients With Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2012.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}